Despite recent advances in the targeted therapy of breast cancer based on patterns of ER, PgR, and HER2 receptor expression, which have resulted in the extension of survival rates, the identification and validation of a targeted therapy for patients with TNBC is currently one of the most urgent needs in breast cancer therapeutics [12]. The gene discussed is PGR; the disease is breast carcinoma.